Bolt Biotherapeutics (BOLT)
Develops Boltbody immune-stimulating antibody conjugates for cancer.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $5.8 per share a year ago.
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Grows By 355.3%
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 22,704 shares, a growth of 355.3% from the March 31st total of 4,987 shares. Based on an average daily volume of 21,902 shares,
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago.
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update.
Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review
Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Profitability This table compares Nkarta and Bolt Biotherapeutics'
Bolt Biotherapeutics to Participate in Upcoming March Conferences
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 83.8% in December
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 352 shares, a decrease of 83.8% from the December 15th total of 2,177 shares. Approximately 0.0% of the shares of the company are sold short. Based
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks Consensus Estimate of a loss of $5.07. This compares to a loss of $8 per share a year ago.
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CSE Bulletin: Consolidation - Bolt Metals Corp. (BOLT)
Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Bolt Metals Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty five (25) pre-consolidated common shares. As a result, the number of outstanding shares will be reduced to approximately 4,378,388 common shares.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks Consensus Estimate of a loss of $6.4. This compares to a loss of $11.2 per share a year ago.
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline,” said Willie Quinn, President and Chief Executive Officer. “We are now conducting a Phase 1 dose-escalation study for patients with gastric and gastroesophageal cancer in Australia, and will expand to other countries in the second half of 2025. We look forward to presenting initial data in the first half of 2026. We also continue to seek a partner for further development of our dectin-2 agonist antibody BDC-3042, which demonstrated activity in lung cancer patients in the form of a partial response (PR) at the highest dose tested. Patients at the highest doses also had a strong immune response consistent with our expectations based on preclinical data.”
Squarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)
Squarepoint Ops LLC purchased a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,971 shares of the company’s stock, valued at approximately $26,000. Squarepoint Ops LLC owned about 0.13% of Bolt Biotherapeutics as of its most recent SEC filing. Separately, Millennium Management LLC purchased a new position in Bolt Biotherapeutics in the fourth quarter valued at approximately $25,000. Institutional investors own 86.70% of the company’s stock. Bolt Biotherapeutics Stock Performance Shares of BOLT opened at $6.64 on Wednesday. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market cap of $254.58 million, a PE ratio of -3.88 and a beta of 0.91. The company’s 50 day simple moving average is $6.76 and its 200-day simple moving average is $8.90. Bolt Biotherapeutics, Inc. has a 12-month low of $5.20 and a 12-month high of $15.60. Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($5.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.80) by $1.00. The business had revenue of $1.22 million for the quarter, compared to analyst estimates of $0.77 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. As a group, equities analysts predict that Bolt Biotherapeutics, Inc. will post -1.61 EPS for the current year. Wall Street Analysts Forecast Growth Several equities analysts have commented on the stock. Stifel Nicolaus dropped their price target on shares of Bolt Biotherapeutics from $25.00 to $20.00 and set a “hold” rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday, March 25th. Finally, Lake Street Capital initiated coverage on shares of Bolt Biotherapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $80.00 target price on the stock. Check Out Our Latest Stock Analysis on BOLT Bolt Biotherapeutics Profile (Free Report) Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.28 per share a year ago.
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We continue to make progress advancing our pipeline of first-in-class, novel immunotherapies,” said Willie Quinn, Chief Executive Officer. “We recently presented promising early clinical data for BDC-3042 at AACR and launched a process to find a partner to accelerate BDC-3042 development. We also just opened enrollment for the first next-generation Boltbody™ ISAC in our pipeline, BDC-4182. We are excited to see what our ISAC platform technology can do for gastric and gastroesophageal cancer patients. We continue to be good stewards of capital as we execute against our mission to deliver new treatment options to patients with cancer.”
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update.